Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

British Journal of Cancer
Gerald Hj MickischM Nuijten

Abstract

Bevacizumab plus interferon-alpha2a (IFN) prolongs progression-free survival to >10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have different tolerability profiles; therefore, costs for managing adverse events may be an important factor in selecting therapy. Costs of managing adverse events affecting patients with metastatic RCC eligible for treatment with bevacizumab plus IFN or sunitinib were evaluated using a linear decision analytical model. Management costs were calculated from the published incidence of adverse events and health-care costs for treating adverse events in the United Kingdom, Germany, France and Italy. Adverse event management costs were higher for sunitinib than for bevacizumab plus IFN. The average cost per patient for the management of grade 3-4 adverse events was markedly lower with bevacizumab plus IFN compared with sunitinib in the United Kingdom (euro1475 vs euro804), Germany (euro1785 vs euro1367), France (euro2590 vs euro1618) and Italy (euro891 vs euro402). The main cost drivers were lymphopaenia, neutropaenia, thrombocytopaenia, leucopaenia and fatigue/asthaenia for sunitinib; and proteinuria, fatigue/asthaenia, ble...Continue Reading

References

Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Dec 24, 2003·The Cancer Journal·Diane D Davey
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David B Solit, Neal Rosen
Feb 9, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J FerlayP Boyle
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald M BukowskiDavid McDermott
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Apr 15, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B MelicharB Escudier
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzJim Cassidy
May 28, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Négrier
Oct 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolas MagnéCyrus Chargari

❮ Previous
Next ❯

Citations

Nov 28, 2013·Expert Opinion on Emerging Drugs·Charlotte DomblidesAlain Ravaud
Feb 11, 2011·Expert Opinion on Pharmacotherapy·Stavros SfoungaristosPetros Perimenis
Oct 1, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Saroj NiraulaIan F Tannock
Jan 1, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Chan ShenYa-Chen T Shih
Jul 21, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·George DranitsarisSeth Woodruff
May 8, 2018·Oncology Research and Treatment·Karin BergerHelmut Ostermann
Jul 24, 2012·The Journal of Urology·Robert FiglinChristopher G Wood
Aug 13, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Timo T Purmonen
May 5, 2018·American Journal of Clinical Oncology·Jacques RaphaelDavid M Naimark
Apr 25, 2020·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Lotte WesterinkMaarten J Postma
Apr 1, 2020·Frontiers in Pharmacology·Maddalena Centanni, Lena E Friberg
Feb 17, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·George DranitsarisSeth Woodruff
May 3, 2021·Oral Oncology·Leticia Rodrigues-OliveiraAna Carolina Prado-Ribeiro
Sep 1, 2021·Expert Opinion on Drug Safety·Shunji Takahashi
Oct 26, 2021·Frontiers in Endocrinology·Thierry BrueGérald Raverot

❮ Previous
Next ❯

Software Mentioned

Excel

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.